Tesamorelin Side Effects: What Egrifta's Own FDA Label Reports

Our companion article on sermorelin's side effects opens with a fact that reframes the whole question: sermorelin has no current FDA-approved label, so there's no official adverse-reaction section to quote for it. Tesamorelin is the opposite case. It has a real, current, FDA-approved label — Egrifta SV's structured product label, in force today — with a specific, numbered set of warnings and a published adverse-reaction table from a 543-patient safety population. This article reports what that label actually says, not what a compounding pharmacy's marketing page paraphrases from it.

Seven numbered warnings, read directly off the label

Egrifta SV's label organizes its safety concerns into seven numbered sections. Here is what each one states, without softening any of them:

5.1 — Increased Risk of Neoplasms. The label's own reasoning is mechanistic and stated in one sentence: tesamorelin "induces the release of endogenous growth hormone (GH), a known growth factor." Patients with active malignancy are not to be treated with it at all — that's a contraindication, not just a caution. Patients with a history of treated and stable malignancy are to start only "after careful evaluation of the potential benefit of treatment relative to the risk of re-activation of the underlying malignancy," and treatment is to stop "if there is any evidence of recurrent malignancy¹." The label adds a population-level note worth keeping in view: HIV-positive patients already carry an elevated background malignancy risk independent of tesamorelin, which is part of why the decision to start treatment is framed as a careful one.

5.2 — Elevated IGF-1 Levels. This section states plainly that "the effects of prolonged elevations in IGF-1 levels are unknown" — not that they're known to be harmful, and not that they're known to be safe. It instructs monitoring IGF-1 during therapy and considering discontinuation for persistent elevations above 3 standard deviation scores (SDS). The label quantifies how often that actually happens: among patients treated for 26 weeks, 47% had IGF-1 above 2 SDS and 36% above 3 SDS, with the effect visible as early as week 13. Among those who stayed on treatment for a full 52 weeks, 34% remained above 2 SDS and 23% above 3 SDS at the end of treatment¹.

5.3 — Fluid Retention. Attributed directly "to the induction of GH secretion," manifesting as increased tissue turgor and musculoskeletal discomfort — edema, arthralgia, and carpal tunnel syndrome are named specifically — which the label describes as "either transient or resolve with discontinuation of treatment¹."

5.4 — Glucose Intolerance or Diabetes Mellitus. During clinical trials, 5% of tesamorelin-treated patients reached an HbA1c of 6.5% or higher from baseline to week 26, versus 1% on placebo — an intent-to-treat hazard ratio of 3.3 (95% CI, 1.4 to 9.6) for developing diabetes by that measure. The label instructs evaluating glucose status before starting and monitoring periodically throughout treatment, and separately flags that patients with existing diabetes should be monitored for retinopathy given the IGF-1 increase¹. See the section below — this is the one place this article states a real tension in the evidence rather than resolving it quietly.

5.5 — Hypersensitivity Reactions. Occurred in 4% of Egrifta-treated patients in clinical trials — pruritus, erythema, flushing, urticaria, and rash are named. Patients are advised to seek prompt medical attention and stop treatment immediately if one is suspected¹.

5.6 — Injection Site Reactions. Erythema, pruritus, pain, irritation, and bruising, occurring in 25% of Egrifta-treated patients during the first 26 weeks versus 14% on placebo. The label's own mitigation is rotating injection sites within the abdomen¹.

5.7 — Increased Mortality in Patients with Acute Critical Illness. This one is easy to miss because it doesn't come from tesamorelin's own trials directly — the label draws it from the broader literature on pharmacologic growth hormone doses in critically ill patients (complications following open-heart surgery, abdominal surgery, multiple trauma, or acute respiratory failure), and instructs considering discontinuation in critically ill patients given that tesamorelin, as a GHRH analog, stimulates the same GH pathway¹. It is a real, separate labelled warning, not a restatement of the neoplasm or glucose sections.

The full adverse-reaction table, as published

That table comes from the label's own §6.1, covering 543 patients who received Egrifta and 263 who received placebo during the initial 26-week controlled phase of the pivotal trials — the same pooled trial population behind tesamorelin's approval¹. The label's own framing of the dominant pattern: "The most commonly reported adverse reactions were hypersensitivity reactions..., edema-related reactions..., hyperglycemia, and injection site reactions¹." Nothing in that list is exotic; it is the direct, mechanistic consequence of raising growth hormone pharmacologically, applied to a specific trial population.

A real tension, stated rather than resolved

Here is the one place this article deliberately does not pick the more comfortable framing. The pooled Phase 3 trial itself — published in full, peer-reviewed, by the investigators who ran it — reports in its own abstract: "No clinically meaningful differences were observed between groups in glucose parameters at wk 26 and 52²," and its 52-week safety-extension follow-up separately states changes in glucose parameters "were not clinically significant³." Read those two sentences alone, and tesamorelin looks metabolically neutral.

The label's own §5.4, built from the same trial program, reports a statistically significant hazard ratio of 3.3 (95% CI 1.4–9.6) for crossing a diabetic HbA1c threshold on tesamorelin versus placebo¹. Both statements are true, and the reason they don't contradict each other is that they're measuring different things: the trial publications describe mean changes in glucose parameters across the treatment groups as a whole, while the label's hazard ratio describes how many individual patients crossed a specific diagnostic threshold (HbA1c ≥ 6.5%) — a categorical outcome that a "no meaningful mean difference" framing can genuinely coexist with, because a subset of patients crossing a threshold doesn't have to move the group average by much. This article states that distinction directly rather than quoting whichever sentence sounds more reassuring: the trial authors' own conclusion is that tesamorelin didn't meaningfully shift glucose on average, and the label's own required disclosure is that it measurably raised the odds of an individual patient becoming diabetic by lab criteria. Both belong in an honest answer.

What this means for a compounded tesamorelin purchase

Every number above describes the FDA-approved Egrifta product, dosed at 1.4 mg or 1.28 mg daily depending on formulation — our page on the label's actual dosing covers that in full — administered to a specific population (HIV patients with lipodystrophy) under trial-level or prescriber-level supervision. It doesn't describe what's in a compounded tesamorelin vial sold for general wellness use, which isn't FDA-reviewed for identity or concentration and may differ from the approved product entirely. What it does establish is the honest baseline: even the FDA-approved version of this drug carries a real neoplasm warning, a real glucose-tolerance signal, and a labelled contraindication in critical illness — not hypothetical risks invented by this article, but the sponsor's own required disclosures.

If tesamorelin's narrow HIV-lipodystrophy indication isn't your situation and you're weighing a growth-hormone-axis compound for general use, it's worth being direct about what this site can actually help with: our sermorelin provider rankings are this site's only board covering that category — no reviewed provider here sells tesamorelin. Our head-to-head on sermorelin and tesamorelin covers why that split exists, and our comparison of sermorelin's own side-effect evidence is the place to see how a drug with no current label at all gets evaluated, by contrast with this one.

The bottom line

Tesamorelin's current FDA label carries seven numbered warnings: increased malignancy risk with a contraindication in active disease, elevated IGF-1 with unknown long-term effects, fluid retention, a statistically significant increase in the odds of developing diabetes by HbA1c criteria, hypersensitivity reactions in 4% of patients, injection site reactions in a quarter of patients, and increased mortality risk specifically in acute critical illness. The trial publications behind the drug's approval separately describe its average effect on glucose as not clinically meaningful — both statements are accurate, and this article reports both rather than choosing the one that reads better.